Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome Aysegul Oruc, Yavuz Ayar, Berna Aytac Vuruskan, Abdulmecit Yildiz, Nimet Aktas, Mahmut Yavuz, Mustafa Gullulu, Kamil Dilek, Alparslan Ersoy

Eculizumab as a treatment for atypical hemolytic uremic syndrome secondary to carfilzomib Candela Moliz, Eduardo Gutiérrez, Teresa Cavero, Beatriz Redondo, Manuel Praga

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3 Emanuel Ferreira, Nuno Oliveira, Maria Marques, Luís Francisco, Ana Santos, Armando Carreira, Mário Campos